Close Menu

NEW YORK – Precision medicine firm Lucence Diagnostics announced on Friday that its laboratory in Singapore has been CLIA certified.

As a result, Lucence can receive patient specimens from the US for testing with its LiquidHallmark liquid biopsy blood test. The test detects cancer-causing gene mutations and viruses present in 14 types of cancers, the company said. According to its website, Lucence's liquid biopsy tests use amplicon-based technology to detect cancer signals in blood "more accurately through amplification."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.